Global Retirement Partners LLC Reduces Holdings in Sanofi $SNY

Global Retirement Partners LLC lessened its position in shares of Sanofi (NASDAQ:SNY) by 52.3% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 11,637 shares of the company’s stock after selling 12,746 shares during the quarter. Global Retirement Partners LLC’s holdings in Sanofi were worth $549,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Raymond James Financial Inc. increased its stake in Sanofi by 81.3% during the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after acquiring an additional 2,635,867 shares during the last quarter. Regal Partners Ltd grew its holdings in shares of Sanofi by 102.3% during the 2nd quarter. Regal Partners Ltd now owns 1,548,204 shares of the company’s stock worth $74,794,000 after purchasing an additional 782,838 shares during the period. NewEdge Advisors LLC increased its position in shares of Sanofi by 1,853.1% during the 2nd quarter. NewEdge Advisors LLC now owns 731,208 shares of the company’s stock worth $35,325,000 after purchasing an additional 693,770 shares during the last quarter. American Century Companies Inc. increased its position in shares of Sanofi by 29.3% during the 2nd quarter. American Century Companies Inc. now owns 1,959,185 shares of the company’s stock worth $94,648,000 after purchasing an additional 443,941 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in Sanofi by 9.9% in the 2nd quarter. Franklin Resources Inc. now owns 4,274,410 shares of the company’s stock valued at $206,497,000 after buying an additional 384,902 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

Shares of SNY stock opened at $48.13 on Friday. The firm has a 50 day moving average of $49.24 and a two-hundred day moving average of $48.86. The stock has a market capitalization of $117.39 billion, a PE ratio of 11.27, a P/E/G ratio of 1.21 and a beta of 0.45. The company has a quick ratio of 0.30, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 24th. The company reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $1.31. The business had revenue of $15.46 billion for the quarter, compared to analysts’ expectations of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The company’s revenue for the quarter was down 7.5% compared to the same quarter last year. During the same period last year, the firm earned $2.25 earnings per share. On average, research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the subject of several research analyst reports. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Barclays cut shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday. Cowen reissued a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. Finally, Guggenheim cut Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $62.67.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.